The purpose of this study to assess the MTD and Pharmacokinetics of T0001 in Healthy Adult Chinese Volunteers.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
56
Phase I laboratory of Peking University People's Hospital
Beijing, Beijing Municipality, China
Maximum Tolerance Dose
Time frame: 3 weeks
Adverse events
Time frame: 3 weeks
pharmacokinetics parameter(Cmax, AUC, t1/2, CL, etc)
Time frame: Pre-dose,2、4、12、24、36、48、60、72、84、96、120、144、168、216、264、312、384 and 480hours after the start of subcutaneous injection
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.